LEVAMISOLE AND IMMUNOTHERAPY - SOME THEORETIC AND PRACTICAL CONSIDERATIONS AND THEIR RELEVANCE TO HUMAN-DISEASE

被引：42

作者：

AMERY, WK ^{[1
]}

GOUGH, DA ^{[1
]}

机构：

[1] JANSSEN PHARMACEUT LTD, MARLOW, ENGLAND

来源：

关键词：

D O I：

10.1159/000225546

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：168 / 181

页数：14

共 48 条

[1] AMERY WK, 1978, J RETICULOENDOTH SOC, V24, P187
[2] TIME IN CHEMO-IMMUNOTHERAPY MODELS - AN ABSOLUTE OR A RELATIVE VARIABLE - LESSONS FROM THE LEVAMISOLE EXPERIENCE
AMERY, WK
[J]. INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1979, 1 (01): : 65 - 68
[3] AMERY WK, 1979, CANCER IMMUNOL IMMUN, V7, P191
[4] BARBAIX E, 53 JANSS CLIN RES RE
[5] CABANILLAS F, 1977, P AM ASSOC CANC RES, V18, P328
[6] CHANG P, 1978, P AM ASSOC CANC RES, V19, P370
[7] DAUSSET J, 1977, HLA DISEASE, P11
[8] DEBOIS JM, UNPUBLISHED
[9] DL-2-OXO-3-(2-MERCAPTOETHYL)-5-PHENYLIMIDAZOLIDINE - SULFHYDRYL METABOLITE OF LEVAMISOLE THAT INTERACTS WITH MICROTUBULES
DEBRABANDER, M
AERTS, F
GEUENS, G
VANGINCKEL, R
VANDEVEIRE, R
VANBELLE, H
[J]. CHEMICO-BIOLOGICAL INTERACTIONS, 1978, 23 (01) : 45 - 63
[10] GALVEZ CA, 1978, 12TH INT CANC C WORK, P28